Nonetheless, despite these limitations, these data highlight the noninferiority and safety profile of E100 compounded testosterone pellets as compared with the more expensive Testopel in the treatment of men with TD. Additionally, this study focused on the safety and noninferiority of E100 as compared with Testopel, and sexual dysfunction represents an important entity in the constellation of symptoms that patients with TD may experience. In our trial, a significant percentage of men from both arms exhibited low levels of serum testosterone at the 4-month follow-up. However, levels were not statistically different at the 4- and 6-month time points (Table 2). At 2 months, the median testosterone level was 543.0 ng/dL for the Testopel group and 696 ng/dL for the E100 group. The cut-off of 300 ng/dL was chosen based on the mean total testosterone levels cited in the best available literature with a view to maximizing the potential benefit from prescribing testosterone while minimizing the risks of such treatment. Prior to initiating treatment, clinicians should counsel patients that, at this time, it cannot be stated definitively whether testosterone therapy increases or decreases the risk of cardiovascular events (e.g., myocardial infarction, stroke, cardiovascular-related death, all-cause mortality). Some studies suggest that supplements like ashwagandha could increase testosterone levels, improving muscle mass and strength when combined with resistance training. Drop sets are an advanced strength training technique bodybuilders and fitness enthusiasts use to promote muscle growth and strength. As you can see, there’s an array of benefits to increasing testosterone and gaining muscle. It’s a simple formula for naturally increasing both testosterone and your ability to pack on more quality muscle mass. Exercise will boost testosterone, though certain types of exercise increase testosterone more than others. This is an awesome method to increase your workout intensity and make your muscles work harder. Likewise, while some literature suggests that food ingestion might affect testosterone levels, the evidence is particularly weak, and the Panel does not recommend that clinicians insist on fasting prior to testing. Among men with traditional (10p.m. to 6a.m.) sleep patterns, peak testosterone values occur around 3-8a.m., with 32-39% of the diurnal total decline occurring within the first 30 minutes of waking.18-23 Older men experience diurnal blunting and more stability in testosterone levels throughout the day, while younger men undergo greater variation. Likewise, while some literature suggests that food ingestion might affect testosterone levels, the evidence is particularly weak, and the Panel does not recommend that clinicians insist on fasting prior to testing.Circadian Rhythm. Given the growing concern and need for proper testosterone therapy, the AUA identified a need to produce an evidence-based document that informs clinicians on the proper evaluation and management of testosterone deficient patients. When in doubt—especially with rapidly rising hematocrit, significant PSA changes, uncontrolled hypertension, or new cardiopulmonary symptoms—clinicians generally hold therapy and reassess before resuming at a lower dose or different schedule. If numbers or side effects drift in the wrong direction, the next step is usually a small dose reduction, a change in injection frequency, or a brief pause rather than a leap to higher testosterone dosing. Most clinicians titrate gradually, then reassess labs and symptoms after 3–6 months, following principles laid out in the Endocrine Society guideline. A safe testosterone dosage is the lowest amount that controls symptoms while keeping safety labs within accepted limits. This is why guidelines anchor dosing changes to timed labs plus symptoms, not to a predicted math outcome (summarized in the Endocrine Society guideline). The categorization of evidence strength is conceptually distinct from the quality of individual studies. Evidence tables (for included studies) and evidence profiles (showing estimates of effect for the outcomes of interest) were generated and presented to the Panel. Randomized controlled trials (RCTs) were sought for effectiveness questions, whereas both randomized and non-randomized studies were sought for adverse events and questions of association and risk factors. To be scientifically accurate, the Panel chose the term testosterone deficiency. Clinicians may use aromatase inhibitors, human chorionic gonadotropin, selective estrogen receptor modulators, or a combination thereof in men with testosterone deficiency desiring to maintain fertility. The long-term impact of exogenous testosterone on spermatogenesis should be discussed with patients who are interested in future fertility. One trial with three years of follow-up showed near linear, time-dependent improvements in BMD.202 These findings are similar to other prospective, controlled data, which report an estimated 5% per year increase in BMD in men on testosterone therapy.309 Declining bone density may necessitate additional medical intervention, such as weight bearing exercise, calcium, vitamin D, or bisphosphonate medications. An increase in BMD is an important potential benefit of testosterone therapy for men who might be at risk for LTBF. Improvements in sex drive were also assessed in another meta-analysis performed by Bolona et al.298 Using a variety of measures, the authors demonstrated improvement with a pooled effect of 1.31 (31% increase in sex drive) among men treated with testosterone, with greater improvements noted among men with lower baseline testosterone levels. The presence of ASCVD risk factors is not a contraindication to starting testosterone therapy; however, the optimization of modifiable risk factors in such patients using lifestyle and medical management strategies is recommended and may be best addressed by the patient's primary care provider.
